Latest Regulatory News

Carbonxt Group Limited reported a 7.1% revenue increase and a significant EBITDA improvement in FY25, while commissioning delays at its Kentucky facility temper near-term optimism.

Alligator Energy Limited offers Placement Participants up to 278 million options exercisable at $0.047 each, following a $17.25 million placement completed in June 2025. The options offer closes on 8 September 2025 and is exclusive to Placement Participants.

Alligator Energy has lodged a Prospectus for Placement Options following its June 2025 capital raise, setting the stage for potential shareholder dilution and future funding opportunities.

Carbonxt Group Limited reported a 7.1% revenue increase to $16.2 million in FY25 alongside a 16.7% reduction in net loss, while progressing its Kentucky liquid-phase activated carbon facility and navigating ongoing liquidity challenges.

Phoslock Environmental Technologies reports a sharp revenue increase driven by Brazil and international markets, yet continues to face significant losses and ongoing legal challenges.

Resonance Health reports robust FY25 results with 29% revenue growth and outlines ambitious FY26 guidance targeting $17 million in revenue and $2 million EBITDA. The company’s transformation into three profit-generating segments underpins its expanding footprint in the global clinical trial ecosystem.

Blue Energy Limited has successfully raised $3.2 million through a two-tranche placement, complemented by a proposed $250,000 share purchase plan, to fund drilling and pipeline development in Queensland’s North Bowen Basin.

DGL Group Limited reported a 3% revenue increase to $481.5 million for FY25 but swung to a $24.6 million net loss driven by asset impairments and operational challenges. The company is undertaking significant restructuring and integration efforts to restore profitability.

Staude Capital Global Value Fund Limited has announced a fully franked ordinary dividend of AUD 0.033 per share for the half-year ending June 2025, accompanied by a dividend reinvestment plan offering a 2.5% discount.

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.

4DMedical reports a robust 56% revenue increase in FY2025, driven by SaaS expansion and strategic partnerships, while advancing FDA clearance for its innovative CT – VQ™ lung imaging software.